CClinicalTrials.gg
CompletedNCT05243108Updated Jan 29, 2025

Targeting Aging and Promoting Longevity with Exogenous Nucleotides (TALENTs)

An interventional study of dietary nucleotides and placebo in Aging, sponsored by Peking University. Completed at 1 site in China. Open to participants aged 60 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Peking University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
60 Years to 70 Years
Sex
All
01

Study summary

To investigate the effects of dietary nucleotides (NTs) as an anti-aging supplement, a clinical trial is carried as a randomized, double-blind, parallel design, placebo-controlled. A total of 120 subjects will be enrolled in the study, and they shall be randomly distributed between the two arms, NTs-treated, and placebo-control. They would be given several measurements, including physical examination, questionnaire survey, clinical and aging-related biomarkers tests at 0 (baseline), 2, and 4 months during the RCT.

Read the detailed description

To explore the anti-aging effects of NTs and the regulation of aging-related diseases, this study plans to recruit 120 people as subjects and conduct randomized controlled trials with NTs as an intervention for 4 months. Based on computer-generated random numbers, participants who meet the inclusion criteria are randomly assigned equally to two groups: placebo control and nucleotide intervention groups. In this study, the specific nucleotide composition is 5'-AMP、5'-CMP、5'-GMPNa2、5'-UMPNa2 prepared according to the ratio of 16:41:19:24, which is consistent with the ratio in breast milk and meets the requirements of national infant formula addition and special medical food formula. The dose of 1.2 g/day used is currently approved as the ingredient dose of nucleotides in conventional commercially available health food products. At the 0、2 and 4 months of the study, comprehensive geriatric health assessment, aging biomarker testing and biological sample collection will be conducted. Among them, the comprehensive evaluation of elderly health status is carried out by physical examination and questionnaire survey, including physical health, physiological function, quality of life, cognitive function, psychosocial health, and other aspects of information. The physical examination involves both physical assessment and functional assessment, including body composition, neck circumference, waist circumference, hip circumference, middle arm circumference, calf circumference, BMR, grip strength, six-minute walk, intima-media thickness, subcutaneous AGEs, and spirometry. The scale includes health status, nutritional status, cognitive status, physical activity, and dietary status. Blood samples were used to detect the safety and senescence-related indicators of the subjects. The index system covers four modules and seventeen dimensions, including blood routine, blood biochemistry, inflammatory factors, immune antibodies, T lymphocyte subtypes, oxidative stress level, cancer markers, leukocyte telomere length, DNA methylation, γ-H2A. Blood samples are sequenced simultaneously for gene and transcriptome sequencing. Fecal samples are collected for metagenomic sequencing of intestinal flora.

02

Conditions studied

  • Aging

Keywords

  • anti-aging
  • DNA methylation age
  • Insulin Sensitivity/Resistance
03

In context

Lead sponsor

Peking University is the lead sponsor of 411 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Male/females of 60 to 70 years of age
  2. No serious physical or mental illness
  3. Able to provide written Informed Consent
  4. Able to follow verbal and written study directions
  5. Must not be taking or be willing to take any supplements containing any form of nucleotides for one year prior to baseline and for the duration of the study.
  6. Able to maintain consistent diet and lifestyle habits throughout the study
  7. Willing to consume assigned supplement (NTs or placebo) for 4 months

Exclusion criteria

Exclusion Criteria:

  1. Participants on the current use of prescription or over-the-counter nucleotides
  2. Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator
  3. Documented presence of atherosclerotic disease and/or cardiopulmonary disease
  4. History of drug or alcohol abuse
  5. History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements
  6. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.
  7. Currently, or within the past 30 days, enrolled in a different clinical investigation
  8. Inability to provide a venous blood sample
  9. Unable or unwilling to provide written informed consent for participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    NTs Intervention group

    The subject of 1200mg has been given orally once a day for 4 months.

    Dietary Supplement: dietary nucleotides

  • Placebo comparator
    placebo control group

    The ingredients, dosage, and usage are the same as experimental.

    Dietary Supplement: placebo

Interventions

  • Dietary supplementdietary nucleotides

    1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;

  • Dietary supplementplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. DNAmAge

    DNA methylation clocks were assessed through whole-genome bisulfite sequencing (WGBS).The median of four principal component (PC)-corrected clocks (Horvath, Hannum, GrimAge, and PhenoAge) was chosen as the DNA methylation age outcome measure.

    Time frame: Baseline、At 2 months、At 4 months

  2. The length of Leukocyte telomere

    Telomere length was quantified via quantitative PCR, using telomeric DNA amplification compared to a reference gene.

    Time frame: Baseline、At 2 months、At 4 months

Secondary outcomes

  1. glycolipid metabolic profile

    fasting glucose, glycated hemoglobin, fasting insulin, HOMA-IR, triglycerides, total cholesterol, LDL-C, HDL-C

    Time frame: Baseline、 At 2 months、 At 4 months

  2. Body composition

    BIA method - fat mass (grams), lean mass (grams) and total mass (grams).

    Time frame: Baseline、At 2 months、At 4 months

  3. Phenotypic Age

    Phenotypic Age=141:50+ln(0.00553\*ln(1-xb)). xb=-19:907-0.0336\*albuminþ+0.095\*creatinine+0.0195\*glucose+0.0954\*lnCRP-0.0120\*lymphocyte percent+0.0268 mean cell volume+0.3356 red blood cell distribution width+0.00188 alkaline phosphatase+0.0554\*white blood cell count+0.0804\*chronological age

    Time frame: Baseline、 At 2 months、 At 4 months

  4. Spontaneous fluorescence of subcutaneous AGEs

    AGEs test

    Time frame: Baseline、At 4 months

  5. Carotid thickness of intima media

    ultrasound

    Time frame: Baseline、At 2 months、At 4 months

  6. The levels of MDA

    In serum

    Time frame: Baseline、At 2 months、At 4 months

  7. The levels of GSH-Px

    In serum

    Time frame: Baseline、At 2 months、At 4 months

  8. The levels of SOD

    In serum

    Time frame: Baseline、At 2 months、At 4 months

  9. Body circumference

    Measured with a soft tape - waist, hip, mid-arm, neck and calf circumference

    Time frame: Baseline、At 4 months

  10. Gait speed

    6m walking time/speed test

    Time frame: Baseline、At 4 months

  11. The score of the Short Physical Performance Battery (SPPB)

    The SPPB is a composite test that includes assessments of gait speed, a balance test, and a chair stand test. The maximum score is 12 points, and a score of ≤ 8 points indicates poor physical performance.

    Time frame: Baseline、At 4 months

  12. Time costs of TUG

    For the Timed-Up and Go test, individuals are asked to rise from a standard chair, walk to a marker 3 m away, turn around, walk back and sit down again.

    Time frame: Baseline、At 4 months

  13. Grip strength

    Calibrated handheld dynamometer.

    Time frame: Baseline、At 4 months

  14. Pittsburgh sleep quality index (PSQI)

    Items are categorized into seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleep medication, and daytime dysfunction. The possible score range for each component is 0 (no difficulty) to 3 (severe difficulty). The seven component scores are summed to produce a global score; higher scores represent poorer subjective sleep quality.

    Time frame: Baseline、 At 4 months

  15. Score of Montreal Cognitive Assessment (MoCA)

    Scores range from 0-30 (+1 for 12 or fewer years of education); a score of 26 or higher indicates normal cognitive functioning, while a score of 25 or lower indicates impaired functioning.

    Time frame: Baseline、At 4 months

  16. The levels of TNF-α in serum

    Suspension array

    Time frame: Baseline、 At 2 months、 At 4 months

  17. The levels of IL-1 in serum

    Suspension array

    Time frame: Baseline、 At 2 months、 At 4 months

  18. The levels of IL-6 in serum

    Suspension array

    Time frame: Baseline、 At 2 months、 At 4 months

  19. The levels of ICAM-1 in serum

    Suspension array

    Time frame: Baseline、 At 2 months、 At 4 months

  20. Methylation damage

    Blood sample

    Time frame: Baseline、 At 4 months

  21. The level of telomere repeat binding factors-1 (TRF-1)

    Blood sample

    Time frame: Baseline、 At 4 months

  22. T lymphocyte subsets

    CD3+, CD4+, CD8+ were analyzed using flow cytometry

    Time frame: Baseline、 At 2 months、 At 4 months

  23. γH2AX

    Phosphorylated histone H2AX (p-H2AX) was measured via ELISA

    Time frame: Baseline、 At 2 months、 At 4 months

Other outcomes

  1. Gut microbiota

    Total bacterial DNA was extracted from fecal samples, followed by 16S-targeted amplification, high-throughput sequencing, species annotation and abundance analysis to describe the intestinal microecological structure and diversity of the subjects

    Time frame: Baseline、At 4 months

  2. Scores of Quality of life

    Quality of life was measured 36-Item Short Form Survey (SF-12) questionnaire. The items are grouped into eight domain scores: physical functioning, role limitations due to physical health, pain, general health, energy, social functioning, role limitations due to emotional problems and emotional well-being. Domain scores can be collapsed to a physical component summary Physical health (PCS) and a mental component summary Mental health (MHS). Each score ranges from 0 to 100, with higher values representing the better self-perceived health-related quality of life.

    Time frame: Baseline、At 4 months

  3. Dietary intake

    Dietary intake was assessed using a combination of the 24-hour dietary record (24HR) method and the Food Frequency Questionnaire (FFQ)

    Time frame: Baseline、 At 4 months

07

Study locations

1 site
  • Talents project team
    Chengdu, Sichuan 610095, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243108
Lead sponsor
Peking University
Responsible party
Meihong Xu (Associate professor, Peking University) — Principal investigator
First posted
Feb 16, 2022
Start date
Aug 23, 2022
Primary completion
Mar 29, 2023
Completion
Mar 29, 2023
Last update
Jan 29, 2025

Study contacts

Meihong Xu, Assis prof.
principal investigator · Peking University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion